neuro42 develops portable, robotic, and AI-driven MRI platforms designed to deliver real-time neuroimaging and interventional guidance at the point of care. The company’s FDA-cleared systems aim to make high-quality MRI accessible outside traditional imaging suites, enabling timely diagnostic and procedural support. Its approach combines mobility, automation, and AI-powered analysis to enhance efficiency and clinical decision-making. neuro42 positions its technology within regulated medical imaging and interventional care contexts.

The technology integrates compact MRI hardware with robotic positioning and AI algorithms that guide image acquisition, processing, and interpretation. This allows clinicians to obtain high-resolution brain images and actionable insights in real time. Portability and automation reduce dependence on fixed infrastructure and specialized operators, while AI enhances image quality, workflow, and procedural support. The platform emphasizes safety, reproducibility, and usability in diverse clinical environments.

neuro42 targets hospitals, emergency care settings, and research institutions requiring rapid, on-site neuroimaging and interventional guidance. The platform is intended to complement traditional MRI workflows and support point-of-care diagnostics and interventions. Its positioning reflects broader interest in mobile, AI-enhanced imaging technologies that expand access to advanced neuroimaging and real-time clinical decision support.